MedTrace Logo

Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction

NCT06555614 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-04-28

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the safety of Acellular Dermal Matrix(ADM) processed by CO2 supercritical fluid technology against other acellular dermal matrix products from different companies that have been washed with detergents in patients undergoing breast reconstruction surgery with implants due to the breast cancer.

Conditions

  • Breast Cancer Female
  • Breast Reconstruction

Interventions

OTHER

Acellular Dermal Matrix(ADM)

A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.

Sponsors & Collaborators

  • DOF Inc.

    lead INDUSTRY

Principal Investigators

  • Kiyong Hong, Ph.D · Seoul National University Hospital

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2026-12-31
Completion
2027-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555614 on ClinicalTrials.gov